SCHEMBL4567337

SCHEMBL4567337

CC(C)=CCCC(C)(C)c1cc(C)cc(O)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 3/20 0.40
HIF1A Q16665 1/20 0.38
EPAS1 Q99814 1/20 0.38
PTPN1 P18031 2/20 0.38
BACE1 P56817 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CNR1 P21554 5/20 0.35
CNR2 P34972 5/20 0.35
APP P05067 1/20 0.35
MAOB P27338 1/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPK1 P28482 1/20 0.35
KMT2A Q03164 1/20 0.35
CHRNA7 P36544 1/20 0.35
STAT3 P40763 1/20 0.35
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34
SRC P12931 1/20 0.34
ALOX5 P09917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4570709 0.81 HIF1A (0.43) ALOX15HIF1AEPAS1BACE1ALDH1A1
SCHEMBL31545824 0.70 GABRA1 (0.40) HIF1AEPAS1BACE1CNR1CNR2
SCHEMBL3359223 0.68 GABRA1 (0.71) ALOX15HIF1AALDH1A1MEN1KMT2A
SCHEMBL11102324 0.68 ALDH1A1 (0.57) ALOX15HIF1APTPN1ALDH1A1CNR1
SCHEMBL24507201 0.68 PPARG (0.43) ALOX15HIF1AEPAS1
SCHEMBL22459188 0.68 MEN1 (0.44) ALOX15HIF1AEPAS1MEN1KMT2A
SCHEMBL22458751 0.68 ALOX15 (0.39) ALOX15HIF1AEPAS1
SCHEMBL4567341 0.68 CNR1 (0.35) CNR1CNR2
SCHEMBL4567340 0.66 CNR2 (0.44) CNR1CNR2
SCHEMBL30994196 0.65 ALDH1A1 (0.52) ALOX15HIF1APTPN1BACE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9173867-B2 Treatment of immune dysregulation using cannabinoid derivatives IMMUGEN PHARMACEUTICALS, INC. (US) 2015-11-03 US disclosed
US-20140066497-A1 TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES IMMUGEN PHARMACEUTICALS, INC. 2014-03-06 US disclosed
US-8586767-B2 Method for treatment of HIV and diseases of immune dysregulation TRAVIS CRAIG RICK (US) 2013-11-19 US disclosed
US-20120289589-A1 Treatment Of Immune Dysregulation Using Cannabinoid Derivatives TRAVIS CRAIG RICK (US) 2012-11-15 US disclosed
US-20120122917-A1 Method For Treatment Of HIV And Diseases Of Immune Dysregulation TRAVIS CRAIG RICK (US) 2012-05-17 US disclosed
US-20080108647-A1 Treatment of HIV and diseases of immune dysregulation TRAVIS CRAIG R 2008-05-08 US disclosed
US-20070179135-A1 Cannabinoid derivatives TRAVIS CRAIG R 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066497-A1 TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES CNR2, CNR1, GPR18 ALOX15 480/4885HIF1A 1207/4885EPAS1 1857/4885
US-20120289589-A1 Treatment Of Immune Dysregulation Using Cannabinoid Derivatives CNR2, CNR1, GPR18 ALOX15 480/4885HIF1A 1207/4885EPAS1 1857/4885
US-20120122917-A1 Method For Treatment Of HIV And Diseases Of Immune Dysregulation CNR2, CNR1, ICOS ALOX15 357/4885HIF1A 1357/4885EPAS1 2505/4885
US-20070179135-A1 Cannabinoid derivatives CNR2, CNR1, GPR18 ALOX15 1156/4885HIF1A 1606/4885EPAS1 2311/4885
US-20080108647-A1 Treatment of HIV and diseases of immune dysregulation CNR1, CNR2, ICOS ALOX15 340/4885HIF1A 1129/4885EPAS1 1989/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.